#BioFigures: 3,000 whole genomes sequenced to fight Parkinson!

18/02/2015 - 2 minutes

WHO?

23andMe, founded in 2006, is the leading personal genetics company dedicated to helping people access, understand and benefit from the human genome. The vision for 23andMe is to personalize healthcare by making and supporting meaningful discoveries through genetic research.

23andMe1

Photo credit: 23andMe

WHAT?

23andMe, announced an agreement with Genentech, a member of the Swiss Roche Group, to generate whole genome sequencing data for approximately 3,000 people in 23andMe’s Parkinson’s disease community. This multi-year collaboration provides Genentech with the ability to identify potential therapeutics based on genome sequencing and survey data from the largest Parkinson’s disease community of its kind. Following the conclusion of the collaboration, 23andMe will have the ability to conduct additional research on the data, as well as the ability to make the information available to Parkinson’s researchers from around the world.

 23 and me

Photo credit: 23andMe

WHY?

Parkinson’s is an extremely complex disease, which affects approximately 1 in every 500 people,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!